IL17A and psoriasis: Currently, case reports have indicated that nivolumab, pembrolizumab, durvalumab, and atezolizumab may induce or exacerbate psoriasis (7).While the specific mechanisms underlying ICI-induced psoriasis remain controversial, the overexpression of Th1/Th17-specific cytokines, such as IL-17, following blockade of PD-1 may be involved (8).Our case provides the first documented evidence of Toripalimab-induced psoriasis flare in a patient with esophageal cancer.